文献速递胸部肿瘤

检查点抑制剂肺炎对接受免疫检查点免疫治疗的NSCLC患者生存的影响

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
PubMed 文献 · J Thorac Oncol · 2018-11-30

该研究基于205例接受免疫检查点抑制剂(ICI)治疗的NSCLC患者队列,采用多状态模型分析发生检查点抑制剂肺炎(CIP)对死亡风险的影响。发现发生CIP独立增加死亡风险,且该风险增加仅见于腺癌组织学患者。

要点

  • 在ICI治疗的NSCLC患者中,发生CIP独立增加死亡风险。
  • 多因素模型中,CIP相关死亡风险增加仅见于腺癌组织学患者。
  • 启动ICI后第一年内,发生和从CIP恢复的风险均增加。

核心结论

  • 在NSCLC中,发生CIP使接受免疫治疗患者的生存恶化。

研究设计与样本

  • 利用205例接受ICI治疗的NSCLC患者队列收集的基线和随访数据,采用多状态建模方法分析发生CIP对死亡风险的影响。

主要发现

  • 观察到发生CIP和从CIP恢复的风险随时间变化,启动ICI后第一年内发生和恢复的风险均增加。
  • 在调整和未调整模型中,发生CIP均独立增加向死亡转换的风险。
  • 在多因素模型中,CIP相关的死亡风险增加仅见于腺癌组织学患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With increasing use of immune checkpoint inhibitors (ICIs) for advanced NSCLC, there is increasing recognition of immune-related adverse events associated with ICI use. We recently reported increased incidence of checkpoint inhibitor pneumonitis (CIP) in ICI-treated NSCLC patients. Since development of immune-related adverse events in other organ systems has been associated with either no change or even improvement in tumor response/cancer outcomes, we sought to better understand the impact of CIP development on overall survival in ICI-treated NSCLC patients. Using baseline and follow-up data collected on a cohort of 205 ICI-treated NSCLC patients, we used a multi-state modeling approach to understand the effect of developing CIP on the risk of death. We observed time-dependent changes in risk of developing and recovery from CIP, with an increased risk of both developing and recovering from CIP in the first year after initiating ICI. We found that developing CIP independently increased the risk of transitioning to death in both adjusted and unadjusted models. In the multivariate model, we found that the increase in mortality associated with CIP was only seen in patients with adenocarcinoma tumor histology. Collectively, these findings suggest that in NSCLC, development of CIP worsens survival in patients receiving immunotherapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Suresh K, Psoter KJ, Voong KR, et al. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. J Thorac Oncol. 2018. PMID: 30503891. doi:10.1016/j.jtho.2018.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。